Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
2026 Revenue Guidance Falls Short of Expectations, BioNTech(BNTX.US)Plunges Over 20%
On Tuesday, BioNTech (BNTX.US) plummeted over 20% in early trading, marking its largest decline since April 25, and is currently trading at $80.20. According to recent news, the company’s adjusted Q4 losses and full-year 2026 revenue guidance both fell short of analyst expectations. The company reported a diluted adjusted loss of €0.33 per share for Q4, compared to a profit of €1.79 per share a year earlier. Analysts surveyed by FactSet expected a loss of €0.16 per share. Quarterly revenue as of December 31 was €907.4 million, down from €1.19 billion a year earlier. Analysts forecasted revenue of €768.3 million. For 2026, the company expects revenue between €2 billion and €2.3 billion, while analysts’ consensus from FactSet is €2.75 billion.
Additionally, BioNTech SE’s founder will leave the company to establish a new biotech firm focused on messenger RNA (mRNA) technology, which is the core technology behind its blockbuster COVID-19 vaccine.